ACCORD HEALTHCARE LAUNCH LENALIDOMIDE ACCORD 5 MG, 10 MG, 15 MG, 20 MG & 25 MG HARD CAPSULES

Accord Healthcare is delighted to announce the launch of another High-Tech medicine to their already extensive range of High-Tech medicines, Lenalidomide Accord 5 mg, 10 mg, 15 mg, 20 mg & 25 mg which come in pack sizes of 21 Hard Capsules.

Accord have teamed up with HealthBeacon to create an online portal for pharmacists to order and administer Lenalidomide. Pharmacists can register their pharmacy, review the risk management materials, complete the risk management paperwork and order Lenalidomide Accord via the HealthBeacon Lenalidomide portal. To register on the portal visit www.patientsafetyhub.ie . Once registered and logged in, demonstration videos explaining how to use the portal are also available.

Auditing requirements are the responsibility of Accord Healthcare Ireland.

Lenalidomide Accord is indicated for treatment of:

Multiple myeloma

Lenalidomide Accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.  Lenalidomide Accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.  Lenalidomide Accord in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.

Myelodysplastic syndromes

Lenalidomide Accord as monotherapy is indicated for the treatment of adult patients with transfusion dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.

Mantle cell lymphoma

Lenalidomide Accord as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

Follicular lymphoma

Lenalidomide Accord in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1-3a).

Please refer to the Summary of Product Characteristics (SPC) for further information. The SPC is available from at www.hpra.ie and for Healthcare Professionals here.